ABBV-838

DRUG2 trials

Sponsors

AbbVie

Conditions

Multiple Myeloma

Phase 1

Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

TerminatedNCT02462525

AbbVieMultiple Myeloma

Start: 2015-05-06End: 2017-12-06Updated: 2018-09-13

A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

WithdrawnNCT02951117

AbbVieMultiple Myeloma

Start: 2017-08-31End: 2021-04-28Updated: 2017-06-05

Related Papers

First-in-Human Phase I Study of ABBV-838, an Antibody–Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma

Clinical Cancer Research2020-01-2227 citations